HC Wainwright

Checkpoint Therapeutics Inc (NASDAQ: CKPT), a nano-cap therapeutics company that focuses on developing anti-cancer agents, has lost more than half of its value over the past few months but some analysts are bullish on the longer-term picture. The Analyst H.C. Wainwright's Joseph Joseph...

Commercial-stage biopharma company Corium International Inc (NASDAQ: CORI) reported Thursday 19 percent revenue growth for its fiscal year fourth quarter of 2017, while its loss per share narrowed to 36 cents from 42 cents. The company also detailed a slew of upcoming catalysts, including a Dec....

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on Tuesday reported second-quarter earnings, which consisted of a better than expected loss per share (53 cents versus expectations for 62 cents)and a revenue beat ($35.6 million versus expectations for $32.03 million). Sales of the company's only...

Shares of TESARO Inc (NASDAQ: TSRO) were trading higher by nearly 2 percent early Thursday morning after the U.S. Food and Drug Administration granted approval to the company's intravenous version of its therapy to treat nausea and vomiting in adults undergoing chemotherapy. An oral version of the...

Strata Skin Sciences, Inc. (NASDAQ: SSKN), a nano-cap medical technology company that develops, commercializes and markets innovative products for the treatment of dermatologic conditions, has a more than 400 percent upside, according to HC Wainwright & Co's Joseph Pantginis. Pantginis...

Despite a more than 200-percent gain in MannKind Corporation (NASDAQ: MNKD)'s stock over the past month alone analysts at H.C. Wainwright see even further upside ahead. The firm's Oren Livnat initiates coverage of MannKind's stock with a Buy rating and $7 price target, which represents a gain of...

Following the failure of Axovant Sciences Ltd (NASDAQ: AXON)'s late-stage MINDSET study, which evaluated its Alzheimer's treatment candidate intepirdine, Baird said its bull thesis is blown out. However, HC Wainwright said the setback is not the end of the world for the company. Baird...

Analysts at H.C. Wainwright & Co. continue to see Ligand Pharmaceuticals Inc. (NASDAQ: LGND) as a "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares hit a four-month high on Wednesday following the release of strong sales by the company. HC Wainwright said underlying marketing dynamics give them confidence going forward. The firm reiterated its Buy rating and $60 price target. Analysts Andrew...

Shares of Cara Therapeutics Inc (NASDAQ: CARA) fell nearly 30 percent early Friday morning after the company released concerning top-line results from a phase 2B trial of its oral CR845 therapy for the treatment of pain associated with osteoarthritis of the hip or knee. But not all analysts are...

Axovant Sciences Ltd (NYSE: AXON) reported its fiscal fourth-quarter results on Tuesday, which helped push shares higher by more than 3.5 percent on Wednesday. Investors could potentially be rewarded with another upcoming catalyst in September with topline Phase 3 MINDSET results, analysts at HC...

Inovio Pharmaceuticals Inc (NASDAQ: INO) announced Thursday morning it has commenced a Phase III clinical program (called REVEAL) to evaluate the efficacy of its DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by human papillomavirus. Inovio's study will assess the efficacy...

Following Akebia Therapeutics Inc's (NASDAQ: AKBA) announcement of an expanded agreement with Otsuka (OTC: OTSKY) to develop and commercialize Vadadustat in Europe, China and Other Territories, HC Wainwright said in a note that the European partnership provides strong economics, removing any...

On March 28, Galectin Therapeutics Inc (NASDAQ: GALT) provided an update on the progress of its lead program, the Phase 2b trial of GR-MD-02 in Non-Alcoholic Steato-Hepatitis patients with cirrhosis (NASH-CX). Citing a “more positive view of the therapeutic potential of the mechanism of...